Know Cancer

forgot password

Phase 2 Study on Brain Tumor Uptake of the Amino Acid O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET)

Phase 2
Open (Enrolling)
Brain Neoplasms

Thank you

Trial Information

Phase 2 Study on Brain Tumor Uptake of the Amino Acid O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET)

Radioactively labelled amino acids have been used for years to delineate primary brain
tumors and for the early detection of tumor recurrence. Positron emission tomography studies
indicate that the extent of amino acid uptake correlates to the true histological extent of
gliomas. Recently a fluorine-18 labelled amino acid has been introduced
(O-(2-[F-18]Fluorethyl)-L-tyrosin (FET)), which is suitable for routine use in brain tumor
patients. There is evidence that this amino acid is transported into brain and brain tumors
by the amino acid transport of the L-type. The cDNA of this L-transporter has recently been
cloned and has been shown to be identical to the light chain of the 4F2-antigen (CD98),
which has previously been described as marker of cell growth and proliferation.

The heavy chain of this heterodimer is known to modulate integrins which are thought to play
a fundamental role in glioma invasion.

Besides the evaluation of the diagnostic capability of FET in brain tumors, a comparison of
FET uptake in vivo and CD98 expression ex-vivo is performed with tissue slices as available
after routine surgery in glioma patients.

Inclusion Criteria:

- Patients with suspected primary brain tumors

- CT or MRI showing lesion of >= 2,5 cm

- Any age; parents informed consent in children available

- Karnofsky-Index >= 20 %

- Referral by Depts. of Neurology, Neuro-Oncology, Neurosurgery, or Pediatric Neurology
at the UKM

- Biopsy and/or surgery planned

- Patient is able to lie during the PET scan for 50 minutes without moving • Patient
must be able to give informed consent; signature must be present before the PET scan

Exclusion Criteria:

- Pregnancy or breast feeing

- Patients, who by psychiatric disease are not able to give informed consent

- Complete renal failure

- Inclusion to other studies according to § 23 of the German radiation protection law

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Histological samples where available

Principal Investigator

Matthias Weckesser, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Nuclear Medicine, University Hospital Muenster


Germany: Federal Institute for Drugs and Medical Devices

Study ID:




Start Date:

January 2004

Completion Date:

Related Keywords:

  • Brain Neoplasms
  • Brain neoplasms
  • Positron-Emission Tomography
  • Amino Acids
  • Magnetic Resonance Imaging
  • Brain Neoplasms
  • Neoplasms